secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001193125-26-214976
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar enters $150M ATM equity agreement; appoints Linda Rubinstein as interim CFO
--------------------------------------------------------------------------------

- Equity Distribution Agreement with Guggenheim Securities and H.C. Wainwright for up to $150M of common stock in at-the-market offerings.
- Sandra Gardiner retiring as interim CFO effective May 15, 2026; Linda Rubinstein of FLG Partners will succeed her.
- Rubinstein has over 35 years experience, raised >$5B in financings, and previously CFO of Adverum Biotechnologies.
- Shares may be sold through ordinary brokers' transactions on Nasdaq at market prices; 3.0% commission fee to agents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/d159808d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-214976

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer